Examkin

Question

Difficulty: Very hardNeurocognitive Disorders

During a routine home-visit evaluation, a geriatric psychiatrist examines a 73-year-old man whose daughter reports a 9-month history of progressive cognitive decline and unusual behaviors. The daughter emphasizes that his mental clarity fluctuates dramatically; he can be highly alert in the morning but profoundly lethargic and disorganized by the afternoon. Over the past 3 months, he has started seeing "strangers sitting on the living room couch," which causes him significant distress and agitation. For the past 4 years, he has exhibited violent thrashing and shouting movements during sleep. His medical history is significant for major depressive disorder, for which he has taken fluoxetine continuously for the last 5 years. Vital signs are within normal limits. Neurologic examination demonstrates bilateral cogwheel rigidity and a mild resting tremor in the left upper extremity. His Montreal Cognitive Assessment score is 20/30, featuring prominent deficits in visuospatial construction. The physician discusses management options with the daughter to address the patient's distressing visual hallucinations. Which of the following is the most appropriate next step in the pharmacologic management of this patient's condition?

  1. Initiate a central acetylcholinesterase inhibitorAnswer
  2. B
    Initiate haloperidol for acute agitation management
  3. C
    Initiate selegiline to target the patient's motor symptoms
  4. D
    Diagnose schizophreniform disorder and initiate risperidone
  5. E
    Increase the fluoxetine dosage to treat psychotic features of bipolar depression

Answer

The correct answer is to initiate a central acetylcholinesterase inhibitor.
The correct answer involves initiating a central acetylcholinesterase inhibitor (such as rivastigmine or donepezil). This patient's presentation of progressive cognitive decline, prominent fluctuations in alertness, recurrent well-formed visual hallucinations, parkinsonism (rigidity, resting tremor), and REM sleep behavior disorder is the classic clinical triad/tetrad for Major Neurocognitive Disorder with Lewy Bodies (DLB). In patients with DLB, acetylcholinesterase inhibitors are considered the first-line pharmacotherapy. They effectively reduce the frequency and severity of visual hallucinations and improve cognitive fluctuations. Importantly, they achieve this without carrying the severe morbidity and mortality risks associated with antipsychotic medications in this specific patient population.

Step-by-Step Solution

1
Identify the primary underlying syndrome based on the clinical presentation.
The combination of fluctuating cognition, well-formed visual hallucinations, parkinsonism (rigidity, resting tremor), and REM sleep behavior disorder establishes a diagnosis of Major Neurocognitive Disorder with Lewy Bodies (DLB).
Accurate diagnosis is required because DLB has unique pharmacological sensitivities compared to other neurocognitive disorders.
2
Determine the primary goal of the requested intervention.
The patient requires management for distressing visual hallucinations and agitation.
Treatment should target the specific symptom causing the most distress while avoiding harm to the patient.
3
Select the safest and most effective initial pharmacotherapy for DLB.
Central acetylcholinesterase inhibitors (e.g., rivastigmine, donepezil) are the treatment of choice.
These medications safely improve both cognitive and neuropsychiatric symptoms (including hallucinations) in DLB without the severe risks associated with antipsychotics.
4
Evaluate the remaining options for dangerous drug interactions or contraindications.
Haloperidol is ruled out due to the risk of severe neuroleptic sensitivity in DLB; selegiline is ruled out due to the risk of Serotonin Syndrome when combined with the patient's current fluoxetine prescription.
Ruling out dangerous psychopharmacological interactions confirms the safety and necessity of the correct choice.

Key Concept

Major Neurocognitive Disorder with Lewy Bodies presents with fluctuating cognition, visual hallucinations, parkinsonism, and REM sleep behavior disorder; initial pharmacotherapy for cognitive and behavioral symptoms should utilize acetylcholinesterase inhibitors while strictly avoiding typical antipsychotics.
Rate this question

Topics

Neurocognitive Disorders

More questions from this topic